-
Ann Rheum Dis: Initial joint use of Alyson Tan and Dallanon to treat connective tissue disease-associated pulmonary hypertension (CTD-PAH)
Time of Update: 2020-05-29
The study was designed to assess the effectiveness of the initial combination therapy (COMB), as well as baseline characteristics and risk stratification, in the primary group of connective tissue
-
Ann Rheum Dis: Bimekizumab Double Middle and Lemynesin-17A and 17F Therapeutic Aggressive Syllitis
Time of Update: 2020-05-29
Bimekizumab selective lymes (IL)-17A and IL-17F The efficacy and safety of bimekizumab in a phase IIb dose-range study of active syllable scoliosis (AS) are reported here randomly divided adult A
-
Gastroenterology: Microcolitis and Risk of Inflammatory Bowel Disease
Time of Update: 2020-05-29
Colitis under the microscope has a common mechanism for causing disease with inflammatory bowel disease (IBD) Researchers recently used data from a national queue study to examine the relationship
-
Ann Rheum Dis: The efficacy and safety of hedonist mono-anti-subcutaneous administration to treat hip or knee osteoarthritis
Time of Update: 2020-05-29
In a study that included 24 weeks of treatment and 24 weeks of safe follow-up, the efficacy of neurogrowth factor inhibitors, tanyzumab, for the treatment of hip or knee osteoarthritis (OA) was ana
-
Semin Arthritis Rheu: Endemic Osteopathic Disease: Bone Joint Disease from a Food Source
Time of Update: 2020-05-29
Osteopathic disease (KBD) is a endemic bone joint disease that can cause disability and a heavy socio-economic burden Precautions have been taken over the past few decades However, it is necessary
-
Nano Lett: Nanostructure surfaces with different elastic modules regulate the immune response by stretching macrophages
Time of Update: 2020-05-29
Reasonable immune response is the key to the successful implantation of biological materials into the human body, and the design and manufacture of biomaterials to regulate immune response is the f
-
Ann Rheum Dis: High prevalence of postpartum arthritis-like MRI lesions in women
Time of Update: 2020-05-29
Bone marrow edema (BMO) on MRI of the sic) joint (SIJs) is a hallmark of the central axis spinal arthritis (SpA), but this injury occurs in healthy subjects in the event of increased mechanical str
-
J Rheumatol: The Challenge of Very Early Systemic Sclerosis: A Mix of Mild and Early Diseases?
Time of Update: 2020-05-29
In order to address the hypothesis that very early systemic sclerosis (SSc) is a group of mild or early patients with heterogeneousness, the degree of heterogeneity in clinical, epidemiological, an
-
Ann Rheum Dis: Is rheumatoid arthritis targeted therapy really effective? Patient Queue Longitudinal Analysis (RA BIODAM)
Time of Update: 2020-05-29
The study aims to explore whether the goal of targeting ( T2T ) strategies in daily clinical practice can lead to more patients with rheumatoid arthritis ( RA ) to achieve remission goals a dis
-
J Rheumatol: rituximaandaandiphosphamide therapy antisynthetic syndrome associated with ILD
Time of Update: 2020-05-29
Anti-synthetic enzyme syndrome (ASyS) correlation interstitial pulmonary disease (ILD) has a poor prognosis Intravenous cyclophosphamide (CYC) and rituxima (RTX) are the main treatments for moderat
-
Ann Rheum Dis: Ultra-early randomized controlled trial using Inasip and MTX vs MTX in combination with Inasip delayed treatment ra
Time of Update: 2020-05-29
This study was designed to confirm that methotrexate in the methotrexate ( ETN-MTX ) is better than MTX targeted therapy ( MTX-TT ) in the ultra-early stage of rheumatoid arthritis ( ERA ) ( 30%
-
Takeda's Vidoju mono-resistance is approved in China for the treatment of moderate to severe active ulcerative colitis and Crohn's disease
Time of Update: 2020-05-29
Takeda Pharmaceuticals announced that its Entyvio (Vidoju mono-resistance) is approved by the China Drug Administration (NMPA) for the treatment of adult patients with moderate to severe active ulc
-
Arthritis Rheumatol: The efficacy and safety of the new JAK3/TEC inhibitor PF-06651600 (ritlecitinib) for moderate to severe rheumatoid arthritis
Time of Update: 2020-05-29
The 2a-phase, eight-week double-blind parallel group study assessed the efficacy and safety of PF-06651600 (ritlecitinib) in patients with rheumatoid arthritis (RA), a nonverse inhibitor in the fam
-
J Thromb Haemost: Antiphospholipid syndrome and the relationship between laboratory positive scant and NBTE prevalence
Time of Update: 2020-05-29
Non-bacterial thrombosis endocarditis (NBTE) is a potential complication of antiphospholipid syndrome (APS) in the form of non-infectious lesions of one or more heart valves There are very limited
-
J Rheumatol: Neurophysiological and immunological characteristics of peripheral nervous system intheiogenic syndrome
Time of Update: 2020-05-29
The purpose of this study was to assess the prevalence, type and association between the presence of autonobodies and the progression of neuropathy in patients with primary dryness syndrome ( pSS )
-
Significant progress! Research finds a new way to avoid the deadly inflammation of COVID-19!
Time of Update: 2020-05-28
May 27, 2020 / Bio-Valley BIOON /- Severe COVID-19 disease can cause excessive inflammation throughout the body, including the lungs, heart and brain Molly Gilligan, a student at the University of
-
The world's first NASH drug! Ocaliva (OCA, Obergecacid) was delayed for the third time in the U.S. review, and Intercept's lead remained unchanged!
Time of Update: 2020-05-28
May 25, 2020 / PRNewswire BIOON/ -- Intercept Pharma is a biopharmaceutical company focused on the development and commercialization of new therapeutic strains for progressive, non-viral liver dise
-
Science reveals new mechanisms for aging! Immune cell defects cause us to age!
Time of Update: 2020-05-28
May 27, 2020 / Bio- BIOON/T-cells should protect us from pathogens, but a new mouse study suggests they may also accelerate aging Blocking cell-induced inflammation or increasing the supply of key
-
Rare disease new drugs! Roche IL-6 monosalysalyzumab has long-term safety in adults and adolescents with psynocoeur cord itisis (NMOSD) adults and adolescents!
Time of Update: 2020-05-28
May 24, 2020 / Biovalley BIOON/ -- Roche recently announced at the 6th Annual Meeting of the European Academy of Neurology (EAN) new aggregated key results for the treatment of psynocopael prototy
-
Lancet: Chinese scientists are the world's first human clinical trial results of the new coronavirus vaccine announced! Results show that the vaccine is safe and can trigger an immune response quickly
Time of Update: 2020-05-28
May 23, 2020 / Bio-Valley BIOON/--- In a new study, researchers from the Institute of Bioengineering of the Chinese Academy of Military Medical Sciences, The Jiangsu Provincial Center for Disease Co
